Semaglutide and obesity treatment: Medical experts address usage and myths

Medical specialists are addressing the growing use and controversy surrounding GLP-1 receptor agonists, such as semaglutide (the active ingredient in Ozempic), for treating obesity. Experts emphasize that obesity is a chronic, multifactorial disease involving genetic, biological, and environmental factors, rather than a simple lack of willpower.

Clinical data indicates that semaglutide can lead to significant weight reduction, with some studies showing an average loss of approximately 17%, and up to 21% in one-third of patients. Beyond weight loss, these medications may offer cardiovascular benefits. However, specialists warn against viewing them as miracle solutions or using them without professional medical supervision.

Common side effects include gastrointestinal issues such as nausea, vomiting, diarrhea, constipation, and abdominal pain. Experts also clarify that weight regain after stopping treatment does not mean the medication failed, but rather reflects the chronic nature of the disease, which may require long-term management alongside lifestyle changes, nutritional support, and physical activity.